期刊
AMERICAN JOURNAL OF TRANSPLANTATION
卷 10, 期 6, 页码 1385-1393出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1600-6143.2009.02997.x
关键词
mTOR inhibitor; nonmelanoma skin cancer; renal transplant; renal transplant recipient; sirolimus; skin tumors
资金
- Amgen
- Astra-Zeneca
- Abbott
- Novartis
- Roche
- Wyeth
- Astellas
- Essex
- Basilea
- Galderma
- Shire
- Stada
- LEO
- Stiefel
- 3M Medica
- Meda
- MDS
- Ellipse
Renal transplant recipients (RTR) have a 50-200-fold higher risk for nonmelanoma-skin cancer (NMSC) causing high rates of morbidity and sometimes mortality. Cohort-studies gave evidence that a sirolimus-based immunosuppression may inhibit skin tumor growth. This single-center, prospective, assessor-blinded, randomized trial investigated if switching to sirolimus treatment inhibits the progression of premalignancies and moreover how many new NMSC occur compared to continuation of the original immunosuppressive therapy. Forty-four RTR (mean age 59.9 years, mean duration of immunosuppression 229.5 months) with skin lesions were randomized to sirolimus or continuation of their original immunosuppression. Blinded dermatological assessment at month 6 and 12 by the same dermatologist evaluated the clinical change compared to baseline. Biopsy was performed in suspected malignancy. Already the 6-month-assessment showed significant superiority of sirolimus-therapy: a stop of progression, even regression of preexisting premalignancies (p < 0.0005). This effect was increased at month 12 (p < 0.0001). Nine patients developed histologically confirmed NMSC: one in the sirolimus group, eight in the control group, p = 0.0176. Sirolimus-based immunosuppression in RTR, even when established many years after transplantation, can delay the development of premalignancies, induce regression of preexisting lesions and decelerate the incidence of new NMSC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据